Contact us

Utlysning - söker patienter med atopiskt eksem för intervju

Vi på TIRmed samarbetar tillsammans med Atopikerna för en patientundersökning. TIRmed Pharma håller just nu på att utveckla en ny kräm...

TIR-C selected for IVA's 100 list

TIRmed Pharma's project to developing TIR-C has been listed by Kungliga IngenjörsVetenskapsakademien (IVA) in their annual 100 list as...

TIRmed Pharma consortium receives grant of 1.5 MSEK from Vinnova

Vinnova, together with Swelife and Medtech4health, have jointly called for new innovative projects within life science and medical...

TIRmed Pharma initiates permeability study with leading CRO

TIRmed Pharma have begun a permeability study on their cream targeting Atopic Dermatitis, TIR-C. The study will showcase its ability to...

TIRmed Pharma raises 5.4 MSEK in equity for pre-clinical development

Eczema is a common disease affecting up to 20% of children and approximately 3% of adults, with a drugs market estimated up to 75 BSEK...

New publication

Amelioration of Compound 48/80-Mediated Itch and LL-37-Induced Inflammation by a Single-Stranded Oligonucleotide Authors: Aleksandra...

TIRmed Pharma receives approval to grant patents in Europe

June 17 - 2020

TIRmed Pharma receives approval of patent in the US

TIRmed Pharma´s proprietary compound to treat inflammatory skin disorders was issued patent approval in the US, April 21st, 2020.

TIRmed Pharma AB

Alviksvägen 1, 167 53 Stockholm